Organisation paid for research Program year 2025 Source: CMS Open Payments

Carmen Michelle Kavali MD PC

Neither a doctor nor a teaching hospital

Research payments

$420,845

33 payments

Through program year 2025, Carmen Michelle Kavali MD PC is reported as receiving $420,845 in research payments, across 33 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$175,245	14
2024	Research	$234,798	17
2023	Research	$7,503	1
2022	Research	$3,300	1

Breakdown

Who paid Research payments · program years 2022–2025

AbbVie, Inc. $420,845 33 payments

Studies the money was for Research payments · program years 2022–2025

BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study $198,308 13 payments
A Prospective Multi-center Open-label Study to Evaluate Subject Satisfaction and Natural Outcomes Following Administration of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects with Upper Facial Lines (Glabellar Lines Lateral Canthal Lines and Forehead Lines) $70,490 9 payments
M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study $57,630 3 payments
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study $36,908 1 payment
M22-974 BOTOX GL-FHL-CFL Phase 4 $14,198 1 payment
M21-417 BOTOX Ph3 Pivotal MMP $9,848 1 payment
A Study to Evaluate the Safety and Effectiveness of JUVEDERM Products in Adult Participants for the Change of Their Overall Facial Appearance $9,000 1 payment
A multicenter, double-blind, randomized, parallel-group, controlled study to evaluate the safety and effectiveness of ELAPR002f injectable gel in adult participants with atrophic acne scars $7,503 1 payment
A Prospective, Multi-center, Open-label Study to Evaluate Subject Satisfaction and Natural Outcomes Following Administration of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects with Upper Facial Lines (Glabellar Lines, Lateral Canthal Lines, and Forehead Lines) $7,503 1 payment
A Prospective, Multi-center, Open-label Study to Evaluate Subject Satisfaction and Natural Outcomes Following Administration of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects with Upper Facial Lines (Glabellar Lines, Lateral Canthal Lines, and Forehead Lines) $6,157 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.